Medication info

Combiplex Lipid Central Injection

Prescription medicationSolution
Ingredient · strength
Glucose Monohydrate›20.9gL-Alanine›1.6gL-Arginine›1.13gL-Lysine Hydrochloride›1.13gSodium Acetate Hydrate›0.817gGlycine›0.79gL-Leucine›0.79gL-Phenylalanine›0.79gL-Valine›0.73gL-Histidine›0.68gL-Proline›0.68gPotassium Chloride›0.597gL-Glutamic Acid›0.56gL-Isoleucine›0.56gL-Methionine›0.56gL-Threonine›0.56gSodium Glycerophosphate Hydrate›0.714gL-Serine›0.45gL-Aspartic Acid›0.34gMagnesium Sulfate Heptahydrate›0.329gL-Tryptophan›0.19gL-Tyrosine›0.023gCalcium Chloride Hydrate›0.098gSoybean Oil›20g
Manufacturer / importer
JW Pharmaceutical Corp.
Appearance
Composed of internal compartments divided into three chambers and an external package. There is an oxygen absorbent pouch between the internal compartments and the external packaging. The compartments of the internal bag each contain:
Packaging
1540ml (Solution A: 790, Solution B: 450, Solution C: 300), 2053ml (Solution A: 1053, Solution B: 600, Solution C: 400)
Approval status
Active

MFDS item code 200802850 · Notified 2008.03.14

Summary

Main use
Improvement of deficiencies in nutrition (amino acids and calories), fluids, and electrolytes
Who uses it
Adults
Adult dosage
○ Adults : The dose and infusion rate are determined according to fat clearance and glucose metabolism. The dose and bag size are determined according to the patient's condition, body weight, and nutritional requirements. - Patients with normal nutritional status or mild metabolic stress: 0.7~1.0 g/kg/day of amino acids (0.10 - 0.15 g nitrogen/kg) - Patients with moderate to severe metabolic stress: Infuse 1.0~2.0 g/kg/day of amino acids (0.15 - 0.30 g nitrogen/kg). In general, infuse 0.7~1.3 g/kg/day of total amino acids (0.10 - 0.20 g nitrogen/kg) into a central vein, corresponding to 19 - 38 mL/kg/day of this medication. ○ Infusion rate : The infusion rate should not exceed 2.6 mL/kg per hour (equivalent to 0.25 g/kg of glucose, 0.09 g/kg of amino acids, and 0.1 g/kg of fat). Administration over 12 - 24 hours is recommended.

Ingredients

Manufacturer
JW Pharmaceutical Corp.

Efficacy & effects

Improvement of deficiencies in nutrition (amino acids and calories), fluids, and electrolytes

View approved original text

This medication provides necessary water, electrolytes, amino acids, and calories for patients who cannot adequately absorb nutrients orally or through the gastrointestinal tract. It primarily supplies nutrition through intravenous administration, improving the nutritional status of patients. This helps prevent complications due to nutritional deficiencies and aids in recovery. It plays an important role in maintaining the patient's nutritional balance, enhancing therapeutic effects. Therefore, it is used as an essential treatment for patients with restricted nutrient intake.

Dosage and Administration

Adult dosage

○ Adults : The dose and infusion rate are determined according to fat clearance and glucose metabolism. The dose and bag size are determined according to the patient's condition, body weight, and nutritional requirements. - Patients with normal nutritional status or mild metabolic stress: 0.7~1.0 g/kg/day of amino acids (0.10 - 0.15 g nitrogen/kg) - Patients with moderate to severe metabolic stress: Infuse 1.0~2.0 g/kg/day of amino acids (0.15 - 0.30 g nitrogen/kg). In general, infuse 0.7~1.3 g/kg/day of total amino acids (0.10 - 0.20 g nitrogen/kg) into a central vein, corresponding to 19 - 38 mL/kg/day of this medication. ○ Infusion rate : The infusion rate should not exceed 2.6 mL/kg per hour (equivalent to 0.25 g/kg of glucose, 0.09 g/kg of amino acids, and 0.1 g/kg of fat). Administration over 12 - 24 hours is recommended.

Precautions

This medication must be used under the direction of a physician. If anaphylactic reactions such as fever, chills, rash, and difficulty breathing occur, administration must be stopped immediately. When used with ceftriaxone, precipitates may form, so the same infusion apparatus must not be used simultaneously. Caution is needed in premature or low-birth-weight infants due to their low lipid elimination ability, which can be risky. Patients with allergies to egg, soybean protein, severe liver dysfunction, hyperlipidemia, or blood clotting disorders should not receive this medication. It should be administered cautiously in patients with renal failure, pancreatitis, liver dysfunction, or any issues with lipid metabolism. During administration, monitoring for abnormal reactions such as fever, chills, nausea, increased liver enzyme levels, and thrombophlebitis is necessary. Serious adverse effects such as lipid overload syndrome may occur, so avoiding overdose is crucial. In the initial phase of administration, closely monitor the patient's condition, and start administering once the electrolyte imbalance is corrected. Aseptic techniques are critical for infection prevention during central venous administration. After administration, blood triglyceride levels must be measured periodically to confirm lipid elimination capability. Regular checks of blood sugar, electrolytes, liver and kidney function, and other parameters must be conducted during the administration. Administration should not be conducted simultaneously with blood, and potential interactions with other medications must be considered. Caution is advised for pregnant or breastfeeding women, and for the elderly, the administration rate should be slowed down and the dose adjusted. Accurate clinical test results can only be obtained after 5-6 hours post-administration, so this must be noted. In the case of overdose, symptoms such as nausea, vomiting, and electrolyte imbalance may appear, and administration must be stopped immediately or slowed down; blood dialysis may be necessary as needed. Do not use if the packaging is damaged, the solution is cloudy or separated, and dispose of any leftover solution after administration. This medication should be stored at temperatures between 0-25°C, and freezing is prohibited.

Side effects

  • Increased body temperature
  • chills
  • nausea
  • vomiting
  • temporary increase in liver enzymes
  • thrombotic venous inflammation
  • hypersensitivity reactions
  • skin rash
  • urticaria
  • hyperventilation
Show 18 more
  • hypertension
  • hypotension
  • hemolysis
  • increased reticulocytes
  • abdominal pain
  • headache
  • fatigue
  • priapism
  • hyperlipidemia
  • fever
  • fat deposition
  • hepatomegaly
  • splenomegaly
  • anemia
  • leukopenia
  • thrombocytopenia
  • blood coagulation disorders
  • coma

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a sealed container to prevent air ingress, and the temperature must be kept below 25 degrees Celsius. Care must be taken to prevent the medication from freezing.

Appearance and packaging

Appearance

Composed of internal compartments divided into three chambers and an external package. There is an oxygen absorbent pouch between the internal compartments and the external packaging. The compartments of the internal bag each contain:

Package unit

1540ml (Solution A: 790, Solution B: 450, Solution C: 300), 2053ml (Solution A: 1053, Solution B: 600, Solution C: 400)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.